A hypothetical respiratory syncytial virus (RSV) vaccine may be cost effective in the elderly Dutch population who are at high risk of contracting RSV infections. Results of the modelling study showed that it would not be cost effective to vaccinate the entire Dutch population aged ≥ 60 ...
EP: 1.Adjuvant RSV Vaccine in Older Adults EP: 2.Non-adjuvant RSV Vaccine in Older Adults EP: 3.RSV Vaccine Efficacy in Pregnancy EP: 4.Who Not to Vaccinate Against RSV Now Viewing EP: 5.RSV Vaccine Administration Timing and Errors EP: 6.Role of the Pharmacist in Vaccinating Again...
Hypothetical RSV vaccine cost effective in the elderly Journal PharmacoEconomics & Outcomes News Volume 252, Issue 1 , p 5 Cover Date 2000-03-01 DOI 10.1007/BF03266907 Print ISSN 1173-5503 Online ISSN 1179-2043 Publisher Springer International Publishing Additional Links Register for Journal Update...
and Exhibition, held December 8 to 12 in New Orleans, Louisiana, Drug Topics sat down with Chelsea Keedy, PharmD, BCACP, clinical assistant professor at the University of Georgia, to discuss How pharmacists can effectively counsel patients who are vaccine hesitant to receive an RSV vacc...
In 2024, the bivalent RSV prefusion F protein-based (RSVpreF) vaccine was approved for the prevention of RSV infection in infants by active immunization of pregnant women. In this study, we assessed the cost-effectiveness of a combined strategy of RSVpreF vaccine and palivizumab in Japanese ...
RSV is a leading cause of respiratory tract disease in infants and the elderly. RSV has limited therapeutic interventions and no FDA-approved vaccine. Gaps in our understanding of virus–host interactions and immunity contribute to the lack of biological countermeasures. This review updates the curren...
There is still no licensed human RSV vaccine, even after more than 6 decades of research. The monoclonal antibody Palivizumab, which is not efficient against ongoing infection, has been administered for prophylaxis only to high-risk infants, due to high cost and limited efficacy [5,6,7]. Very...